Cardiac dysfunction in solid tumours: a neglected problem. A cardio-oncology scoping review
https://spcare.bmj.com/content/early/2023/11/24/spcare-2023-004440
"In conclusion: (1) There is evidence for cardiovascular dysfunction in patients with solid tumour malignancies, distinct from CTRCD. People with solid tumours have higher rates of cardiac disease, even when newly diagnosed and treatment naïve. (2) Abnormalities manifest mainly as cardiomyopathies, ANS dysfunction and raised biomarker levels and are associated with significant symptoms. (3) Treatment plans need to take account of these risks, and widen criteria for screening."
-
- There are more pages in this discussion • 1,069 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.14 |
Change
-0.015(1.30%) |
Mkt cap ! $197.1M | |||
| Open | High | Low | Value | Volume |
| $1.16 | $1.16 | $1.13 | $170.4K | 148.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5868 | $1.14 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.14 | 2062 | 1 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| RAC (ASX) Chart |